中药复方与活性成分治疗胰腺纤维化的机制综述
胰腺纤维化是慢性胰腺炎的核心病理特征和进展驱动因素,目前美国FDA尚无获批的特异性治疗药物。该综述系统总结了胰腺纤维化的发病机制,并全面分析了现有实验研究中中药复方及活性成分防治胰腺纤维化的作用机制,指出中药通过多靶点途径发挥抗纤维化作用,为胰腺纤维化的治疗和研究提供了新思路。
要点
- 中药通过抑制胰腺星状细胞活化、调节细胞外基质降解、抑制巨噬细胞浸润与极化及抑制腺泡细胞凋亡发挥抗纤维化作用。
- 基础研究主要集中于胰腺星状细胞活化及相关信号通路,尤其是TGF-β/Smad、MAPK、NF-κB和Hedgehog等关键通路。
- 中药多靶点作用特点为胰腺纤维化治疗提供了新策略,但现有证据主要来自实验研究。
核心结论
- 中药复方及活性成分通过多靶点机制发挥抗胰腺纤维化作用,具有治疗潜力。
研究设计与样本
- 综述类文章,系统总结胰腺纤维化发病机制并综合分析现有实验研究中中药复方及活性成分的作用机制。
主要发现
- 中药通过抑制胰腺星状细胞活化、调节细胞外基质分解、抑制巨噬细胞浸润与极化以及抑制胰腺腺泡细胞凋亡来对抗胰腺纤维化。
临床怎么用
- 为中医及中西医结合医生理解中药抗胰腺纤维化的多靶点机制提供参考,提示可关注胰腺星状细胞活化及相关信号通路。
局限性
- 现有证据主要来自基础实验研究,临床转化仍需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pancreatic fibrosis (PF), the primary pathological hallmark of chronic pancreatitis (CP), is recognized as a pivotal driver of CP progression. Currently, no therapies are approved by the U.S. Food and Drug Administration (FDA) specifically for PF treatment, highlighting an urgent need for novel therapeutic strategies. Emerging evidence positions Traditional Chinese Medicine (TCM) as a promising multi-target approach against PF. This paper summarizes the pathogenesis of PF and provides a detailed review and comprehensive analysis of the mechanisms underlying Chinese herbal formulas and active ingredients investigated for PF prevention and treatment in existing experimental studies. Numerous studies indicate that TCM combats PF by inhibiting pancreatic stellate cells (PSCs) activation, regulating extracellular matrix (ECM) breakdown, suppressing macrophage infiltration and polarization, and inhibiting pancreatic acinar cell apoptosis. Current basic research predominantly focuses on PSC activation and associated signaling pathways, particularly key pathways such as TGF-β/Smad, MAPK, NF-κB, and Hedgehog. This work thus offers novel insights and approaches for PF treatment and further research.
引用
- Gan K, Hu Y, Liu W, et al. Therapeutic potential of traditional Chinese medicine in pancreatic fibrosis: mechanisms of TCM formulas and active ingredients. Front Pharmacol. 2025. PMID: 41111511. doi:10.3389/fphar.2025.1609569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。